Almirall S.A. (ALM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Almirall S.A. (ALM) has a cash flow conversion efficiency ratio of 0.060x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€88.75 Million ≈ $103.76 Million USD) by net assets (€1.48 Billion ≈ $1.72 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Almirall S.A. fund operations to measure how many days the company can operate on defensive assets alone.
Almirall S.A. - Cash Flow Conversion Efficiency Trend (2005–2024)
This chart illustrates how Almirall S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Almirall S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Almirall S.A. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiamei Food Packaging Chuzhou Co
SHE:002969
|
0.035x |
|
Werner Enterprises Inc
NASDAQ:WERN
|
0.060x |
|
People.Cn Co Ltd
SHG:603000
|
0.020x |
|
Kyndryl Holdings Inc
NYSE:KD
|
0.327x |
|
Ansell Limited
F:PD1A
|
0.031x |
|
CLARIANT ADR 1/SF 4
F:CLRS
|
N/A |
|
TP ICAP GROUP PLC LS -25
F:8D7
|
N/A |
|
First Merchants Corporation
NASDAQ:FRME
|
0.033x |
Annual Cash Flow Conversion Efficiency for Almirall S.A. (2005–2024)
The table below shows the annual cash flow conversion efficiency of Almirall S.A. from 2005 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Almirall S.A. worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €1.49 Billion ≈ $1.74 Billion |
€160.77 Million ≈ $187.95 Million |
0.108x | +69.08% |
| 2023-12-31 | €1.46 Billion ≈ $1.71 Billion |
€93.48 Million ≈ $109.29 Million |
0.064x | -45.69% |
| 2022-12-31 | €1.32 Billion ≈ $1.54 Billion |
€155.10 Million ≈ $181.33 Million |
0.118x | -35.32% |
| 2021-12-31 | €1.29 Billion ≈ $1.50 Billion |
€233.85 Million ≈ $273.40 Million |
0.182x | +43.80% |
| 2020-12-31 | €1.30 Billion ≈ $1.52 Billion |
€164.76 Million ≈ $192.63 Million |
0.126x | -41.38% |
| 2019-12-31 | €1.28 Billion ≈ $1.50 Billion |
€276.15 Million ≈ $322.84 Million |
0.216x | +79.51% |
| 2018-12-31 | €1.19 Billion ≈ $1.39 Billion |
€143.21 Million ≈ $167.43 Million |
0.120x | +2135.49% |
| 2017-12-31 | €1.13 Billion ≈ $1.33 Billion |
€6.09 Million ≈ $7.12 Million |
0.005x | -92.22% |
| 2016-12-31 | €1.52 Billion ≈ $1.78 Billion |
€105.06 Million ≈ $122.82 Million |
0.069x | -40.86% |
| 2015-12-31 | €1.46 Billion ≈ $1.71 Billion |
€170.88 Million ≈ $199.78 Million |
0.117x | -75.81% |
| 2014-12-31 | €1.34 Billion ≈ $1.57 Billion |
€646.93 Million ≈ $756.34 Million |
0.483x | +539.23% |
| 2013-12-31 | €888.33 Million ≈ $1.04 Billion |
€67.11 Million ≈ $78.46 Million |
0.076x | -38.11% |
| 2012-12-31 | €923.67 Million ≈ $1.08 Billion |
€112.75 Million ≈ $131.82 Million |
0.122x | +4.19% |
| 2011-12-31 | €854.71 Million ≈ $999.25 Million |
€100.14 Million ≈ $117.07 Million |
0.117x | -45.02% |
| 2010-12-31 | €819.30 Million ≈ $957.85 Million |
€174.60 Million ≈ $204.13 Million |
0.213x | -38.82% |
| 2009-12-31 | €751.00 Million ≈ $878.00 Million |
€261.60 Million ≈ $305.84 Million |
0.348x | -- |
| 2008-12-31 | €0.00 ≈ $0.00 |
€233.10 Million ≈ $272.52 Million |
x | -- |
| 2007-12-31 | €573.65 Million ≈ $670.66 Million |
€179.03 Million ≈ $209.31 Million |
0.312x | +45.16% |
| 2006-12-31 | €763.21 Million ≈ $892.28 Million |
€164.09 Million ≈ $191.84 Million |
0.215x | +36.46% |
| 2005-12-31 | €898.52 Million ≈ $1.05 Billion |
€141.57 Million ≈ $165.51 Million |
0.158x | -- |
About Almirall S.A.
Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism; antiinfecti… Read more